---
layout: default
title: Cilostazol
parent: 僅模型預測 (L5)
nav_order: 37
evidence_level: L5
indication_count: 0
---

# Cilostazol
{: .fs-9 }

Evidensnivå: **L5** | Förutsagda indikationer: **0** st
{: .fs-6 .fw-300 }

---

## Innehållsförteckning
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Apotekarens bedömningsrapport

</div>

# CILOSTAZOL: Drug Repurposing Evaluation Report

## One-Sentence Summary

Cilostazol (DrugBank: DB01166) is a known phosphodiesterase III (PDE3) inhibitor historically used for intermittent claudication associated with peripheral arterial disease. The TxGNN model has **not yet generated predicted new indications** for this drug, and critical data gaps remain in mechanism of action details, safety information, and regulatory authorization records in Taiwan.

---

## Quick Overview

| Item | Content |
|------|------|
| Drug (INN) | CILOSTAZOL |
| DrugBank ID | DB01166 |
| Original Indication | Not available in evidence pack (known use: intermittent claudication) |
| Predicted New Indication | **None — no TxGNN predictions available** |
| TxGNN Prediction Score | N/A |
| Evidence Level | **L5** (No prediction or supporting studies in this pack) |
| Taiwan Market Status | ❌ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, the TxGNN model has not generated any predicted new indications for Cilostazol, so a mechanistic plausibility assessment cannot be performed at this time.

Based on publicly known pharmacological information, Cilostazol is a selective phosphodiesterase III (PDE3) inhibitor. It works by increasing intracellular cyclic AMP (cAMP) levels, leading to inhibition of platelet aggregation and vasodilation. It is primarily indicated for the symptomatic relief of intermittent claudication in patients with peripheral arterial disease. However, the evidence pack provided does not include detailed MOA data (flagged as Data Gap DG002).

Given its antiplatelet and vasodilatory properties, Cilostazol could theoretically be explored for other vascular or thrombotic conditions. Until the TxGNN model produces specific predictions, no further mechanistic analysis can be conducted.

---

## Clinical Trial Evidence

Currently no TxGNN-predicted indications are available; therefore, no targeted clinical trial search has been performed for a repurposing candidate.

---

## Literature Evidence

Currently no TxGNN-predicted indications are available; therefore, no targeted literature search has been performed for a repurposing candidate.

---

## Taiwan Market Information

Cilostazol currently holds **no active marketing authorizations (許可證)** in Taiwan. No TFDA license records were found.

---

## Safety Considerations

> Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data are currently unavailable in this evidence pack (flagged as Data Gap DG001).

**Note:** Cilostazol carries a known **FDA Black Box Warning** internationally — it is contraindicated in patients with heart failure of any severity due to the class effect of PDE3 inhibitors (increased mortality observed with long-term use of oral milrinone, another PDE3 inhibitor, in heart failure patients). This should be verified against local labelling once Taiwan regulatory data is obtained.

---

## Data Gaps Summary

The following critical data gaps were identified and must be resolved before this candidate can progress:

| Gap ID | Category | Item | Severity | Remediation |
|--------|----------|------|----------|-------------|
| DG001 | Drug Level | TFDA package insert warnings/contraindications | **Blocking** | Download and parse package insert PDF from TFDA website |
| DG002 | Drug Level | Mechanism of Action (MOA) | High | Query DrugBank API |

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN-predicted indications have been generated for Cilostazol. Combined with the absence of Taiwan marketing authorizations and multiple blocking-level data gaps (safety information, MOA), there is insufficient basis to advance any repurposing evaluation at this time.

**To proceed, the following is needed:**
- **TxGNN model prediction execution** — Run the prediction pipeline for Cilostazol to generate candidate new indications
- **MOA data retrieval** — Query DrugBank API to obtain detailed mechanism of action (DG002)
- **TFDA safety data** — Obtain and parse package insert warnings and contraindications (DG001, Blocking)
- **Taiwan regulatory clarification** — Confirm whether Cilostazol has ever been marketed in Taiwan or if it requires a new drug application pathway
- **Drug-drug interaction profiling** — Current DDI query returned no results; verify against additional databases (e.g., DrugBank interactions endpoint, Micromedex)
## Ansvarsfriskrivning

Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning.
Klinisk validering krävs före klinisk tillämpning.

---

